Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 31 | 2023 | 66 | 11.430 |
Why?
|
| Retinal Detachment | 24 | 2023 | 66 | 6.120 |
Why?
|
| Bevacizumab | 22 | 2023 | 281 | 4.890 |
Why?
|
| Angiogenesis Inhibitors | 22 | 2023 | 311 | 4.220 |
Why?
|
| Fluorescein Angiography | 21 | 2019 | 96 | 2.890 |
Why?
|
| Laser Coagulation | 19 | 2023 | 54 | 2.810 |
Why?
|
| Infant, Newborn | 28 | 2023 | 2379 | 1.700 |
Why?
|
| Retina | 12 | 2022 | 213 | 1.690 |
Why?
|
| Visual Acuity | 21 | 2020 | 194 | 1.610 |
Why?
|
| Optic Nerve | 7 | 2015 | 35 | 1.560 |
Why?
|
| Vitrectomy | 13 | 2022 | 52 | 1.510 |
Why?
|
| Intravitreal Injections | 16 | 2023 | 67 | 1.440 |
Why?
|
| Eye Abnormalities | 5 | 2015 | 41 | 1.410 |
Why?
|
| Retinal Telangiectasis | 3 | 2014 | 5 | 1.350 |
Why?
|
| Tomography, Optical Coherence | 9 | 2020 | 130 | 1.240 |
Why?
|
| Retinal Vessels | 8 | 2015 | 58 | 1.210 |
Why?
|
| Vitreous Body | 6 | 2018 | 54 | 1.170 |
Why?
|
| Retinal Ganglion Cells | 4 | 2015 | 66 | 1.140 |
Why?
|
| Gestational Age | 14 | 2023 | 311 | 1.110 |
Why?
|
| Eye Diseases, Hereditary | 2 | 2021 | 8 | 1.000 |
Why?
|
| Retinal Diseases | 7 | 2018 | 90 | 0.960 |
Why?
|
| Infant, Premature, Diseases | 3 | 2021 | 78 | 0.950 |
Why?
|
| Hemangioblastoma | 2 | 2020 | 12 | 0.900 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2020 | 17 | 0.900 |
Why?
|
| Nerve Fibers | 2 | 2015 | 46 | 0.890 |
Why?
|
| Connective Tissue Diseases | 2 | 2021 | 67 | 0.870 |
Why?
|
| Retrospective Studies | 26 | 2023 | 8491 | 0.840 |
Why?
|
| Vitreous Hemorrhage | 5 | 2022 | 11 | 0.830 |
Why?
|
| Retinal Neoplasms | 2 | 2019 | 10 | 0.820 |
Why?
|
| Infant, Premature | 9 | 2023 | 290 | 0.780 |
Why?
|
| Child | 20 | 2022 | 6928 | 0.770 |
Why?
|
| Humans | 70 | 2023 | 86645 | 0.770 |
Why?
|
| Fovea Centralis | 2 | 2019 | 21 | 0.760 |
Why?
|
| Scleral Buckling | 7 | 2020 | 18 | 0.720 |
Why?
|
| Vascular Endothelial Growth Factor A | 8 | 2020 | 407 | 0.720 |
Why?
|
| Infant | 15 | 2023 | 3047 | 0.710 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2014 | 930 | 0.700 |
Why?
|
| Fundus Oculi | 5 | 2019 | 33 | 0.640 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 375 | 0.620 |
Why?
|
| Lasers | 3 | 2023 | 106 | 0.600 |
Why?
|
| Blindness | 3 | 2014 | 41 | 0.600 |
Why?
|
| Follow-Up Studies | 12 | 2022 | 3640 | 0.590 |
Why?
|
| Antibodies, Monoclonal | 4 | 2012 | 1376 | 0.580 |
Why?
|
| Male | 35 | 2020 | 40967 | 0.530 |
Why?
|
| Female | 34 | 2023 | 44534 | 0.530 |
Why?
|
| Macula Lutea | 1 | 2015 | 19 | 0.510 |
Why?
|
| Retinal Perforations | 3 | 2022 | 19 | 0.490 |
Why?
|
| Recurrence | 8 | 2018 | 1139 | 0.480 |
Why?
|
| Retinal Vein Occlusion | 1 | 2013 | 8 | 0.470 |
Why?
|
| Ocular Hypotension | 2 | 2011 | 3 | 0.470 |
Why?
|
| Retinal Artery Occlusion | 1 | 2013 | 12 | 0.470 |
Why?
|
| Child, Preschool | 10 | 2020 | 3613 | 0.440 |
Why?
|
| Retinal Artery | 1 | 2012 | 3 | 0.440 |
Why?
|
| Retinal Vein | 1 | 2012 | 2 | 0.440 |
Why?
|
| Silicone Oils | 2 | 2020 | 3 | 0.420 |
Why?
|
| Microphthalmos | 1 | 2011 | 7 | 0.410 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2011 | 7 | 0.410 |
Why?
|
| Diffusion of Innovation | 1 | 2012 | 71 | 0.410 |
Why?
|
| Conjunctiva | 1 | 2011 | 19 | 0.400 |
Why?
|
| Lasers, Semiconductor | 1 | 2011 | 2 | 0.400 |
Why?
|
| Septo-Optic Dysplasia | 3 | 2019 | 6 | 0.390 |
Why?
|
| Microsurgery | 1 | 2011 | 84 | 0.390 |
Why?
|
| Choroidal Neovascularization | 2 | 2014 | 31 | 0.360 |
Why?
|
| Adolescent | 13 | 2021 | 8982 | 0.360 |
Why?
|
| Uveitis | 1 | 2010 | 29 | 0.360 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 353 | 0.350 |
Why?
|
| Macular Degeneration | 1 | 2010 | 59 | 0.340 |
Why?
|
| Intraocular Pressure | 5 | 2011 | 54 | 0.330 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2007 | 6 | 0.310 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 1 | 2007 | 5 | 0.310 |
Why?
|
| Herpesvirus 3, Human | 1 | 2007 | 43 | 0.310 |
Why?
|
| Arthritis | 2 | 2021 | 46 | 0.300 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2021 | 46 | 0.300 |
Why?
|
| Abnormalities, Multiple | 2 | 2011 | 232 | 0.290 |
Why?
|
| Infant, Extremely Low Birth Weight | 4 | 2016 | 26 | 0.290 |
Why?
|
| Retinal Degeneration | 2 | 2010 | 28 | 0.280 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 81 | 0.280 |
Why?
|
| Eye Infections, Fungal | 2 | 2017 | 14 | 0.270 |
Why?
|
| Uveoparotid Fever | 1 | 2005 | 1 | 0.270 |
Why?
|
| Adult | 17 | 2022 | 25648 | 0.270 |
Why?
|
| Osteoporosis | 1 | 2007 | 121 | 0.270 |
Why?
|
| Ophthalmoplegia | 1 | 2005 | 11 | 0.270 |
Why?
|
| Porphyrins | 1 | 2004 | 39 | 0.250 |
Why?
|
| Glioma | 1 | 2007 | 285 | 0.250 |
Why?
|
| Photosensitizing Agents | 1 | 2004 | 48 | 0.250 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 94 | 0.250 |
Why?
|
| Treatment Outcome | 8 | 2022 | 7993 | 0.240 |
Why?
|
| Cataract Extraction | 2 | 2016 | 31 | 0.240 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 167 | 0.240 |
Why?
|
| Photochemotherapy | 1 | 2004 | 97 | 0.240 |
Why?
|
| Lens, Crystalline | 3 | 2017 | 69 | 0.240 |
Why?
|
| Perfusion | 1 | 2004 | 203 | 0.230 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 239 | 0.220 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2023 | 39 | 0.220 |
Why?
|
| Regional Blood Flow | 2 | 2013 | 197 | 0.220 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 49 | 0.210 |
Why?
|
| Injections | 3 | 2010 | 109 | 0.200 |
Why?
|
| Middle Aged | 13 | 2020 | 25028 | 0.200 |
Why?
|
| Peptides | 1 | 2005 | 639 | 0.200 |
Why?
|
| Retinal Neovascularization | 2 | 2011 | 5 | 0.200 |
Why?
|
| Retinal Dysplasia | 2 | 2010 | 3 | 0.200 |
Why?
|
| Eye Injuries | 1 | 2020 | 15 | 0.190 |
Why?
|
| Optic Disk | 1 | 2000 | 13 | 0.190 |
Why?
|
| Hearing Loss | 2 | 2019 | 56 | 0.190 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 170 | 0.190 |
Why?
|
| Time Factors | 6 | 2020 | 5210 | 0.180 |
Why?
|
| Young Adult | 6 | 2020 | 5976 | 0.180 |
Why?
|
| Intraoperative Complications | 2 | 2011 | 185 | 0.180 |
Why?
|
| Vision, Low | 1 | 2019 | 15 | 0.170 |
Why?
|
| Endophthalmitis | 2 | 2017 | 21 | 0.170 |
Why?
|
| HIV Infections | 1 | 2007 | 772 | 0.170 |
Why?
|
| Fluoresceins | 1 | 2018 | 43 | 0.170 |
Why?
|
| Cerebral Palsy | 1 | 2019 | 90 | 0.170 |
Why?
|
| Loeys-Dietz Syndrome | 1 | 2018 | 21 | 0.170 |
Why?
|
| Hypoxia | 1 | 2004 | 641 | 0.160 |
Why?
|
| Self-Injurious Behavior | 1 | 2020 | 105 | 0.160 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1565 | 0.160 |
Why?
|
| Lens Diseases | 1 | 2017 | 2 | 0.160 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2018 | 87 | 0.150 |
Why?
|
| Candida albicans | 1 | 2017 | 32 | 0.150 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2017 | 16 | 0.150 |
Why?
|
| Odds Ratio | 1 | 2019 | 678 | 0.150 |
Why?
|
| Candidiasis | 1 | 2017 | 36 | 0.150 |
Why?
|
| Abscess | 1 | 2017 | 91 | 0.150 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 6509 | 0.150 |
Why?
|
| Aged | 10 | 2020 | 18415 | 0.140 |
Why?
|
| Vitreoretinal Surgery | 1 | 2016 | 8 | 0.140 |
Why?
|
| Disease Progression | 4 | 2019 | 1531 | 0.140 |
Why?
|
| Ischemia | 2 | 2010 | 243 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2018 | 971 | 0.130 |
Why?
|
| Subretinal Fluid | 1 | 2014 | 2 | 0.120 |
Why?
|
| Histoplasmosis | 1 | 2014 | 25 | 0.120 |
Why?
|
| Genetic Diseases, X-Linked | 2 | 2010 | 34 | 0.120 |
Why?
|
| Reference Values | 2 | 2012 | 674 | 0.120 |
Why?
|
| Functional Laterality | 2 | 2011 | 201 | 0.110 |
Why?
|
| Coloboma | 1 | 2012 | 12 | 0.110 |
Why?
|
| Blood Flow Velocity | 1 | 2013 | 197 | 0.110 |
Why?
|
| Retinal Photoreceptor Cell Outer Segment | 1 | 2012 | 3 | 0.110 |
Why?
|
| Retinal Photoreceptor Cell Inner Segment | 1 | 2012 | 4 | 0.110 |
Why?
|
| Combined Modality Therapy | 3 | 2011 | 1686 | 0.100 |
Why?
|
| Lissencephaly | 1 | 2012 | 22 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 1204 | 0.100 |
Why?
|
| Collagen Type IX | 1 | 2011 | 1 | 0.100 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2011 | 23 | 0.100 |
Why?
|
| Hemangioma | 1 | 2011 | 60 | 0.100 |
Why?
|
| Genes, Recessive | 1 | 2011 | 87 | 0.100 |
Why?
|
| Shaken Baby Syndrome | 1 | 2010 | 1 | 0.100 |
Why?
|
| Artificial Organs | 1 | 2010 | 3 | 0.100 |
Why?
|
| Ofloxacin | 1 | 2010 | 5 | 0.100 |
Why?
|
| Levofloxacin | 1 | 2010 | 7 | 0.100 |
Why?
|
| Oxazolidinones | 1 | 2010 | 11 | 0.100 |
Why?
|
| Acetamides | 1 | 2010 | 26 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2011 | 2207 | 0.100 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2010 | 8 | 0.100 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2010 | 12 | 0.090 |
Why?
|
| Suture Techniques | 1 | 2011 | 135 | 0.090 |
Why?
|
| Cornea | 1 | 2010 | 69 | 0.090 |
Why?
|
| Body Fluids | 1 | 2010 | 36 | 0.090 |
Why?
|
| Mutation | 3 | 2011 | 3968 | 0.090 |
Why?
|
| Glaucoma, Neovascular | 1 | 2009 | 5 | 0.090 |
Why?
|
| Retreatment | 1 | 2010 | 107 | 0.090 |
Why?
|
| Eye Proteins | 1 | 2010 | 128 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2010 | 125 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 894 | 0.090 |
Why?
|
| Prednisone | 2 | 2010 | 258 | 0.080 |
Why?
|
| HIV-2 | 1 | 2007 | 4 | 0.080 |
Why?
|
| Foscarnet | 1 | 2007 | 12 | 0.080 |
Why?
|
| Vitreoretinopathy, Proliferative | 2 | 2018 | 4 | 0.080 |
Why?
|
| Ganciclovir | 1 | 2007 | 49 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2007 | 66 | 0.080 |
Why?
|
| Valine | 1 | 2007 | 69 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 503 | 0.080 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2007 | 3 | 0.080 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2007 | 4 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 64 | 0.080 |
Why?
|
| Acyclovir | 1 | 2007 | 107 | 0.080 |
Why?
|
| Glucocorticoids | 2 | 2010 | 352 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 429 | 0.070 |
Why?
|
| Hyperplasia | 1 | 2007 | 148 | 0.070 |
Why?
|
| Fetal Blood | 1 | 2007 | 90 | 0.070 |
Why?
|
| HIV-1 | 1 | 2007 | 163 | 0.070 |
Why?
|
| Syndrome | 1 | 2007 | 446 | 0.070 |
Why?
|
| Accommodation, Ocular | 1 | 2005 | 3 | 0.070 |
Why?
|
| Anisocoria | 1 | 2005 | 2 | 0.070 |
Why?
|
| Stilbamidines | 1 | 2005 | 1 | 0.070 |
Why?
|
| Axotomy | 1 | 2005 | 8 | 0.070 |
Why?
|
| Glatiramer Acetate | 1 | 2005 | 14 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 746 | 0.070 |
Why?
|
| Cell Count | 1 | 2005 | 195 | 0.060 |
Why?
|
| Rats, Wistar | 1 | 2005 | 297 | 0.060 |
Why?
|
| Algorithms | 2 | 2012 | 1830 | 0.060 |
Why?
|
| Cell Death | 1 | 2005 | 256 | 0.060 |
Why?
|
| Cats | 1 | 2004 | 303 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2007 | 510 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 242 | 0.060 |
Why?
|
| Smartphone | 1 | 2023 | 36 | 0.050 |
Why?
|
| Catheterization | 1 | 2004 | 232 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2023 | 160 | 0.050 |
Why?
|
| Exudates and Transudates | 2 | 2013 | 14 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2004 | 271 | 0.050 |
Why?
|
| Endotamponade | 1 | 2020 | 4 | 0.050 |
Why?
|
| Trauma Severity Indices | 1 | 2020 | 42 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2020 | 303 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 2378 | 0.040 |
Why?
|
| Administration, Ophthalmic | 1 | 2019 | 9 | 0.040 |
Why?
|
| Refraction, Ocular | 1 | 2019 | 9 | 0.040 |
Why?
|
| Angiography | 1 | 2020 | 208 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2010 | 684 | 0.040 |
Why?
|
| Rats | 1 | 2005 | 3990 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 526 | 0.040 |
Why?
|
| Persistent Hyperplastic Primary Vitreous | 1 | 2016 | 1 | 0.040 |
Why?
|
| Retinoschisis | 1 | 2016 | 3 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2017 | 117 | 0.040 |
Why?
|
| Internationality | 1 | 2016 | 69 | 0.030 |
Why?
|
| Operative Time | 1 | 2016 | 127 | 0.030 |
Why?
|
| Cataract | 1 | 2016 | 86 | 0.030 |
Why?
|
| Animals | 2 | 2005 | 26582 | 0.030 |
Why?
|
| Anesthesia | 1 | 2016 | 164 | 0.030 |
Why?
|
| Ranibizumab | 1 | 2014 | 15 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 751 | 0.030 |
Why?
|
| Ophthalmoscopy | 1 | 2012 | 12 | 0.030 |
Why?
|
| Fibrosis | 1 | 2012 | 203 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 3680 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2012 | 285 | 0.030 |
Why?
|
| Walker-Warburg Syndrome | 1 | 2011 | 5 | 0.020 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2011 | 13 | 0.020 |
Why?
|
| Amniocentesis | 1 | 2010 | 31 | 0.020 |
Why?
|
| Linezolid | 1 | 2010 | 3 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 2012 | 101 | 0.020 |
Why?
|
| Birth Weight | 1 | 2011 | 145 | 0.020 |
Why?
|
| Aqueous Humor | 1 | 2010 | 23 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 41 | 0.020 |
Why?
|
| Spasms, Infantile | 1 | 2010 | 30 | 0.020 |
Why?
|
| Vision, Ocular | 1 | 2010 | 71 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 290 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 143 | 0.020 |
Why?
|
| Eye | 1 | 2010 | 111 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2010 | 121 | 0.020 |
Why?
|
| Introns | 1 | 2011 | 289 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 151 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 695 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 3362 | 0.020 |
Why?
|
| Intellectual Disability | 1 | 2010 | 186 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 966 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 826 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2009 | 227 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 2330 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 884 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 1851 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2008 | 332 | 0.020 |
Why?
|
| Software | 1 | 2008 | 654 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 1621 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 4213 | 0.010 |
Why?
|